Scientists have shown for the first time that tumour DNA shed into the bloodstream can be used to track cancers in real time as they evolve and respond to treatment, according to a new Cancer Research UK study published in the journal Nature Communications.
Over three years, researchers at the University of Cambridge took surgical tumour samples (biopsies) and blood samples from a patient with breast cancer that had already spread to other parts of her body. They carefully studied small fragments of DNA from dying tumour cells that are shed into the blood, comparing them with DNA from the biopsy that was taken at the same point in time.
The results show that the DNA in the blood samples matched up with that from the biopsies, reflecting the same pattern and timing of genetic changes appearing as the cancer developed and responded to treatment. The results provide the first proof-of-principle that analysing tumour DNA in the blood can accurately monitor cancer within the body.
Study author Professor Carlos Caldas, senior group leader at the Cancer Research UK Cambridge Institute, said: “This definitively shows that we can use blood-based DNA tests to track the progress of cancer in real time. The findings could change the way we monitor patients, and may be especially important for people with cancers that are difficult to reach, as taking a biopsy can sometimes be quite an invasive procedure.”
The patient in the study had breast cancer that had already spread to a number of other organs. The researchers – part of a collaborative team effort involving the Carlos Caldas and Nitzan Rozenfeld laboratories at the Cancer Research UK Cambridge Institute – were even able to distinguish between the different secondary cancers and examine how each of the tumours was responding to treatment.
Professor Caldas added: “We were able to use the blood tests to map out the disease as it progressed. We now need to see if this works in more patients and other cancer types, but this is an exciting first step.”
The Latest on: Track cancer development
via Google News
The Latest on: Track cancer development
- Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directorson June 25, 2019 at 2:49 pm
“Elizabeth has a strong track record of financial leadership in various roles throughout her career including as a CFO, a venture capitalist and leader of business development groups,” said ... […]
- Tocagen: An Undeserved Selloffon June 25, 2019 at 11:39 am
Investors overreacted to Tocagen’s recent announcement that an Independent Data Monitoring Committee (IDMC) gave its brain cancer drug clinical ... was granted Fast Track designation by the ... […]
- Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Canceron June 25, 2019 at 5:01 am
As the first PFS data read-out is event-driven, the timeline for reporting remains on track for early in 2020 ... company that is a leader in the development of immunotherapeutic products for the ... […]
- City of Hope to invest $1 billion for cancer treatment and research near Irvine’s Great Parkon June 25, 2019 at 12:01 am
This center is on track to open at the end of ... which is overseeing the development of about 10,000 homes around the Great Park. The plan was to build a $200 million, 73,000-square-foot cancer ... […]
- Global Oncology Cancer Blockbuster Drugs Market Outlook By Industry Size, Share, Revenue, Regions And Top Key Players Analysis From 2019-2025on June 20, 2019 at 2:25 am
The report concludes with the profiles of major players in the global cancer blockbuster drugs market. The key market players are evaluated on various parameters such as business overview and recent ... […]
- FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501on June 18, 2019 at 5:17 am
The FDA's Fast Track designation is designed to facilitate the development and expedite the regulatory review of drugs and biologics that have shown the potential to address an unmet medical need ... […]
- Pfizer to buy cancer drug firm for $11.4bnon June 18, 2019 at 12:00 am
Array brings a broad pipeline of targeted cancer medicines in development, as well as a portfolio of out ... “We are very excited by Array’s impressive track record of successfully discovering and ... […]
- Pfizer to Acquire Array BioPharma for $11.4B, Expanding Cancer Pipelineon June 17, 2019 at 7:35 am
“Impressive track record” “We are very excited ... developing innovative small-molecules and targeted cancer therapies,” added Mikael Dolsten, Pfizer CSO and president, worldwide research, development ... […]
- Harvard chemists achieve landmark in drug discovery with synthesis of potent anti-cancer agenton June 17, 2019 at 6:00 am
Known to be a potent anti-cancer agent in mouse studies ... To me this is a kind of track record in drug development." The collaboration between scientists at Eisai and Harvard is an example of ... […]
- Researchers develop technique to track proteins on the surfaces of endoplasmic reticulum in cellson June 17, 2019 at 4:43 am
Researchers from Kanazawa University on the development of a technique to closely track a specific protein on the surfaces ... The sigma-1 receptor is involved neurological disorders and certain types ... […]
via Bing News